2022
Thrombosis questions from the inpatient wards
Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.Peer-Reviewed Original ResearchConceptsCancer-associated thrombosisInpatient wardsPurpura fulminansIntermediate-dose anticoagulationEtiology of thrombocytopeniaMajor clinical trialsCases of thrombosisCoronavirus disease 2019Recent prospective dataCOVID-19Antithrombin replacementAnticoagulation therapyAntiplatelet therapyAntithrombotic therapyAnticoagulation managementMicrovascular thrombosisPlasma transfusionHospitalized patientsAntiplatelet agentsThromboembolic diseasePlatelet countConsensus guidelinesProspective dataClinical trialsDisease 2019COVID-19 and antiphospholipid antibodies
Butt A, Erkan D, Lee A. COVID-19 and antiphospholipid antibodies. Best Practice & Research Clinical Haematology 2022, 35: 101402. PMID: 36494152, PMCID: PMC9568270, DOI: 10.1016/j.beha.2022.101402.Peer-Reviewed Original ResearchConceptsAntiphospholipid antibodiesCOVID-19 patientsAntiphospholipid syndromeCOVID-19Antiphospholipid antibody productionCOVID-19 coagulopathyCOVID-19 shareMechanism of thrombogenesisCOVID-19 vaccinationNeutrophil extracellular trapsActivation of plateletsPathophysiologic featuresClinical outcomesExtracellular trapsSuch antibodiesAntibody productionComplement pathwayPatientsSyndromeAntibodiesConflicting resultsCoagulopathyImmunothrombosisHypercoagulabilityVaccination
2021
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.Peer-Reviewed Original ResearchConceptsLiver sinusoidal endothelial cellsLiver injuryInterleukin-6Sinusoidal endothelial cellsAlanine aminotransferaseLiver histologyD-dimerCOVID-19Primary human liver sinusoidal endothelial cellsSARS-CoV-2 infectionHuman liver sinusoidal endothelial cellsEndothelial cellsSoluble glycoprotein 130IL-6 levelsSmall-interfering RNA knockdownJAK inhibitor ruxolitinibFactor VIII activityProinflammatory factorsInflammatory signalsLarge cohortInhibitor ruxolitinibVWF antigenEndotheliopathyPatientsInjury
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients